What Atox Bio does

Atox Bio is a privately-held biotechnology company founded in 2003 and headquartered in Ness Ziona, Israel. According to firmographic records, the company specializes in infectious diseases, immunomodulators, and critical care therapeutics — a clinical-stage profile consistent with its investor base and scientific leadership. The company was scientifically founded by immunologists Raymond Kaempfer and Gila Arad, and its clinical development is led by Chief Medical Officer Wayne M Dankner. The company's intellectual and operational foundation is rooted in academic immunology research, with no commercialized products disclosed in the available data.

Atox Bio has raised approximately $58.35M across four documented funding rounds spanning 2010 to 2017, with the largest being a $30M Series C in December 2017 led by Arix Bioscience and backed by a syndicate of tier-one healthcare investors including Adams Street Partners, Asahi Kasei, Integra Holdings, Lundbeckfonden Ventures, OrbiMed, SR One, and The Becker Group. Earlier rounds were led by SR One ($23M in 2014) and Esperante Ventures ($3.25M in 2011). This investor roster is characteristic of a serious clinical-stage biotech rather than a commercial-stage pharmaceutical or consumer-products company, and represents the most authoritative data on what Atox Bio actually does.

A significant portion of the scraped source material describes a direct-to-consumer e-commerce operation (atoxbio.com) selling injectable Human Growth Hormone and GLP-1 peptides (Semaglutide, Tirzepatide, Retatrutide, Ozempic) to global consumers via cryptocurrency and PayPal, with warehouses in the USA and Turkey. This material is internally inconsistent with Atox Bio's biotech identity, scientific founders, investor syndicate, and stated therapeutic focus, and is most plausibly attributable to a domain-name collision, brand impersonation, or an unrelated entity that has acquired the atoxbio.com web address. It has therefore been excluded from the substantive description of the company. Investors evaluating Atox Bio should verify the current use and ownership of the atoxbio.com domain, as the divergence between the firm's documented biotech identity and its live web presence is a material diligence item.

Name

Atox Bio

Legal name

Atox Bio

Website

https://atoxbio.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

Atox Bio is a privately-held, clinical-stage biotechnology company founded in 2003 in Ness Ziona, Israel, developing immunomodulators for infectious diseases and critical care, backed by approximately $58M from biotech investors including OrbiMed, Arix Bioscience, and SR One.

Ownership category

akta.pro rank

Product category

Online HGH and Peptide Retail

NAICS

Food (Health) Supplement Retailers (456191)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Health Food & Supplement Stores (CRAHAEAC)

akta.pro secondary industries

Weight Management & Metabolic Supplements (CRADAGAG), Healthy Aging & Cognitive Support Supplements (CRADAGAM), Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine) (AFAJAKAG)

Keywords

• Human growth hormone
• Online pharmacy retail
• Peptide therapy products
• Weight management medications
• Anti-aging injectables

Headquarters

HQ city

Ness Ziona

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2C

Offering type

Digital Commerce or Content

Cost components

Supply Chain, Operations, Marketing or Sales, Technology or R&D, Personnel

Revenue model

1. Pharmaceutical Product Sales: Direct one-time sales of HGH products (Zptropin, Spectros, Genotropin, Somatropin, Cinnatropin), GLP-1 medications (Semaglutide, Tirzepatide, Retatrutide, Ozempic), and related pharmaceuticals through e-commerce storefront. Products sold at varying price points with discounts on select items.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Atox Bio sells pharmaceutical-grade injectable Human Growth Hormone (HGH) kits and pens (Zptropin, Spectros, Ngenla, Somatropin 191aa, Genotropin, Cinnatropin, ZPtrop AQ) along with GLP-1/metabolic peptide products (Semaglutide, Ozempic, Tirzepatide, Retatrutide) directly to individual consumers worldwide through its online storefront at atoxbio.com. Products are positioned for hormone deficiency therapy, bodybuilding/recovery, anti-aging, and weight management, with anti-counterfeit verification systems and published lab purity results as trust mechanisms.

Product overview

Atox Bio operates as an online pharmacy and retailer specializing in pharmaceutical-grade injectable Human Growth Hormone (HGH) products and metabolic peptides. The product portfolio includes multiple HGH brands (Zptropin, Spectros, Ngenla, Somatropin 191aa, Genotropin, Cinnatropin, ZPtrop AQ pen) along with GLP-1 and related peptide products (Semaglutide, Ozempic, Tirzepatide, Retatrutide). Products are sourced from both USA domestic and international manufacturers/suppliers, with some brands originating from Turkish pharmacies. The company offers these products for purposes including hormone deficiency therapy, bodybuilding, anti-aging, and weight management. Pricing ranges from budget-friendly options to premium pharmaceutical formulations, with products tested for purity levels of approximately 96-99%.

Differentiator

Problem solved

Functional benefit

Products and services

• Zptropin 200 IU kit (USA domestic) Human growth hormone kit in 200 IU dosage, sourced from Chinese manufacturers with anti-counterfeit verification codes; priced at $420 on the USA-domestic storefront.
• Spectros 280 IU kit (USA domestic) High-dose HGH kit (280 IU) from Spectrum-Pharma, with security hologram and manufacturer verification code; priced at $610 on the USA-domestic storefront.
• Zptropin 160 IU kit (USA domestic) Human growth hormone kit in 160 IU dosage, sourced from Chinese manufacturers with anti-counterfeit verification codes; priced at $385 on the USA-domestic storefront.
• Spectros 140 IU kit (USA domestic) Spectrum-Pharma HGH kit in 140 IU dosage, with security hologram and verification code; priced at $305 on the USA-domestic storefront.
• Ngenla 72 IU (Long-acting HGH) Long-acting HGH formulation in 72 IU dose designed for sustained-release delivery; priced at $385.
• Somatropin 191aa 150 IU kit (USA domestic) Biosynthetic human growth hormone (191 amino acid sequence, identical to naturally occurring HGH) in 150 IU kit; priced at $365 on the USA-domestic storefront, with Canadian Peptides manufacturer verification.
• Genotropin 36 IU (12 mg) pen Pen-form HGH product with 36 IU / 12 mg dosage, sourced from licensed Turkish pharmacies and verified via QR code through the Turkish Pharmacy Verification System; priced at $340 (limited supply).
• Cinnatropin 30 IU Budget-tier HGH product in 30 IU dose, flagged as a bestseller with 9–16 day international delivery; priced at $125.
• ZPtrop AQ 36 IU Pen (USA domestic) Pen-form HGH delivery system with 36 IU capacity, featuring 60 clicks with each click delivering 0.2 mg (0.6 IU).
• Semaglutide 5 mg GLP-1 receptor agonist peptide in 5 mg dose for weight management and metabolic support; priced at $199.
• Semaglutide 2 mg Lower-dose GLP-1 receptor agonist peptide (2 mg) for weight management and metabolic support; priced at $135.
• Ozempic 1 mg (USA Domestic) Semaglutide-based injectable medication in 1 mg dose for metabolic and weight management purposes; priced at $390 with 2–4 day USA domestic delivery.
• Tirzepatide Premixed Pen 30 mg (USA domestic) Dual GIP/GLP-1 receptor agonist peptide delivered as a premixed pen in 30 mg dose; priced at $295.
• Retatrutide Premixed Pen 30 mg Triple-agonist peptide (GIP/GLP-1/glucagon) delivered as a premixed pen in 30 mg dose for metabolic support; priced at $325.

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered minor.

• Spectrum-Pharma (Spectros)minorOthersSpectros brand manufacturer providing anti-counterfeit verification through spectrum-pharma.com for authenticity checking of Spectros HGH products sold on AtoxBio
• ZPHC (Zptropin)minorOthersZPHC manufacturer providing verification system at zphc.hk for authenticating Zptropin HGH products sold through AtoxBio
• Canadian Peptides (Somatropin 191aa)minorOthersSomatropin 191aa manufacturer with verification system at check-canadapeptides.org for product authenticity verification

Scale indicators2 records

Recent moves5 records

Expansion highlights3 records

Broad incumbents

• Hims & Hers Health: Public online health platform (HIMS) that dispenses prescription HGH and selected peptides through licensed telehealth. Comparable as a consumer-facing online channel for hormone therapy, though operating strictly within US prescription frameworks versus Atox Bio's self-serve model.
• Ro: Large online pharmacy and telehealth provider offering men's health, hormone optimization, and weight-loss treatments. Overlaps on the HGH/peptide customer segment but enforces prescription workflows Atox Bio does not, making it the dominant legitimate alternative.

Direct peers

• Invigor Medical: Online men's health clinic offering HGH, testosterone, and peptide therapies through telehealth consultation. Closest direct peer to Atox Bio's HGH-led product mix, with comparable target buyer and peptide category extension, though more structured prescription pathways.
• Defy Medical: Telehealth clinic focused on hormone optimization, anti-aging, and wellness therapies including HGH and peptides. Comparable in targeting the same off-label/anti-aging buyer persona as Atox Bio via an online-first model.
• Marek Health: Direct-to-consumer men's health brand providing hormone testing and HGH/peptide therapy through telehealth. Comparable as a brand-led, online-first challenger competing for the same self-directed consumer HGH buyer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atox Bio